Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Stock Short Interest Report for October

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a significant drop in short interest in October. As of October 15th, there was short interest totaling 19,178 shares, a drop of 81.8% from the September 30th total of 105,501 shares. Based on an average daily trading volume, of 224,827 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research downgraded shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Daiichi Sankyo Price Performance

Daiichi Sankyo stock opened at $17.91 on Tuesday. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. Daiichi Sankyo has a 52-week low of $14.98 and a 52-week high of $26.80. The firm has a market cap of $33.37 billion, a PE ratio of 20.83, a price-to-earnings-growth ratio of 1.90 and a beta of -0.11. The company’s 50 day moving average is $17.82 and its two-hundred day moving average is $17.79.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%. The company had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, research analysts expect that Daiichi Sankyo will post 0.93 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.